Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab

Elisa Molinelli; Edoardo De Simoni; Oriana Simonetti

doi:10.1016/j.medj.2024.08.005

Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab

Med. 2024 Oct 11;5(10):1197-1199. doi: 10.1016/j.medj.2024.08.005.

Authors

Elisa Molinelli¹, Edoardo De Simoni¹, Oriana Simonetti²

Affiliations

¹ Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy. Electronic address: [email protected].
² Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

PMID: 39395402
DOI: 10.1016/j.medj.2024.08.005

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disorder with a significant negative impact on quality of life. Th17 axis has a central role in the pathogenesis of HS. Kimball et al. demonstrated the efficacy and safety of bimekizumab in two double-blind, placebo-controlled phase 3 studies (BE HEARD I-II), adding a new targeting option to the therapeutic armamentarium of HS.¹.

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Clinical Trials, Phase III as Topic
Hidradenitis Suppurativa* / drug therapy
Humans
Quality of Life
Th17 Cells / immunology

Substances

bimekizumab
Antibodies, Monoclonal, Humanized